To learn more about these conditions and how Praluent helps treat them, see the “What is Praluent used for?” section below. Praluent is given as an injection under your skin. Praluent contains the ...
Paris and Tarrytown, NY - September 12, 2018 - Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License ...
Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein ...
BARCELONA, SPAIN — Treatment with alirocumab (Sanofi/Regeneron Pharmaceuticals), an investigational proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, resulted in significant reductions ...
The US Food and Drug Administration has approved alirocumab (Praluent, Regeneron Pharmaceuticals) injection as add-on therapy for adults with homozygous familial hypercholesterolemia, the agency ...
PARIS and TARRYTOWN, N.Y., Nov. 7, 2018 /PRNewswire/ -- TheNew England Journal of Medicine (NEJM) today published positive detailed results of the 18,924-patient ODYSSEY OUTCOMES trial. The trial met ...
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration approved Praluent (alirocumab) Injection, the first FDA-approved treatment in a new class of drugs ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved the expanded indication for alirocumab injection for adult patients with homozygous ...
The cholesterol drug alirocumab reduced low-density lipoprotein (LDL) cholesterol by 35.6% compared to placebo in adult patients with homozygous familial hypercholesterolemia (HoFH), according to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results